Navigation Links
FDA Approves LUSEDRA(TM) (fospropofol disodium) Injection for Monitored Anesthesia Care (MAC) Sedation
Date:12/14/2008

is an intravenous sedative-hypnotic agent indicated for monitored anesthesia care (MAC) sedation in adult patients undergoing diagnostic or therapeutic procedures.

Important Safety Information

LUSEDRA should be administered only by persons trained in the administration of general anesthesia and not involved in the conduct of the diagnostic or therapeutic procedure. Patients should be continuously monitored during sedation and through the recovery process for early signs of hypotension, apnea, airway obstruction, and/or oxygen desaturation. Facilities for providing cardiopulmonary resuscitation must be immediately available.

The following serious adverse reactions have been reported with the use of LUSEDRA.

    -- Hypotension
       -- Hypotension was reported in 18/455 (4%) patients treated with
          LUSEDRA using the standard or modified dosing regimen.
       -- Patients with compromised myocardial function, reduced vascular
          tone, or who have reduced intravascular volume may be at an
          increased risk for hypotension.

    -- Hypoxemia
       -- Hypoxemia was reported in 20/455 (4%) patients treated with LUSEDRA
          using the standard or modified dosing regimen. Retention of
          purposeful responsiveness did not prevent patients from becoming
          hypoxemic following administration of LUSEDRA.

    -- Respiratory depression
       -- Apnea was reported in 1/455 (< 1%) patients treated with LUSEDRA
          using the standard or modified dosing regimen.

    -- Loss of purposeful responsiveness
       -- LUSEDRA has not been studied for use in general anesthesia. However,
          administration of LUSEDRA may inadvertently cause patients to become
          unresponsive or minimally responsive to vigorous tactile or painful
          stimulation. The incidence of patients who became minimally
          responsive or unresponsive to vigo
'/>"/>
SOURCE Eisai Corporation of North America
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain
2. FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder
3. FDA Approves Rapid-Acting Insulin Apidra(R) for Treatment of Children with Diabetes
4. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
5. F.D.A. Approves SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Cancer Patients Undergoing Chemotherapy
6. FDA Approves First Hepatitis B Viral Load Test
7. U.S. FDA Approves Requip(R) XL(TM), the First and Only Oral Once-Daily Non-Ergot Dopamine Agonist for Parkinsons Disease
8. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
9. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
10. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
11. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... , Dec. 15, 2014 As medical device ... Product Labeling) markup language standard, content teams have a ... skills to work with the standard. Starting January 2015, ... three webinars on the benefits and the critical aspects ... will be facilitated by Howard Shatz , DCL,s ...
(Date:12/15/2014)... MINNEAPOLIS , Dec. 15, 2014   ... ), one of the nation,s largest and most ... of its business units, DaVita Clinical Research ... capabilities to further expand its extensive clinical research ... chronic kidney disease (CKD) and end-stage renal disease ...
(Date:12/15/2014)... LONDON and BOSTON , ... the leading GPCR structure-guided drug discovery and development company, ... patents in the United States ... of these patents in the US significantly strengthens the ... the major pharmaceutical markets. The suite of ...
Breaking Medicine Technology:Data Conversion Laboratory Helping Life Sciences Content Producers Understand the Impact and Benefits of Structured Product Labeling 2Data Conversion Laboratory Helping Life Sciences Content Producers Understand the Impact and Benefits of Structured Product Labeling 3DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 2DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 3DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 4Heptares Extends Global Patent Protection for GPCR-Focused Drug Discovery Platform With Grant of Core Patents in the United States 2
... proud to announce its conference keynote speakers include: Centers ... CBS Evening News Anchor Katie Couric; U.S. ... U.S. Secretary of Commerce Gary Locke. Each will address ... leaders in Washington, D.C. October 18-20 during AdvaMed ...
... Arlington Medical Resources (AMR), a provider of premier ... finds that more than half of all European inpatients ... Sanofi-Aventis,s Clexane (marketed as Lovenox in the U.S. and ... The European Hospital Anticoagulant Market Guide is a ...
Cached Medicine Technology:AdvaMed 2010 Keynote Speakers Announced 2AdvaMed 2010 Keynote Speakers Announced 3European Hospital Anticoagulant Market Dominated by Sanofi-Aventis's Clexane 2
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... 26 As the voice of the global ... Organizations (ACRO) had the honor of presenting before ... 26th, 2009 in Tokyo. ACRO Chair Derek Winstanly, ... and ACRO Executive Director Douglas Peddicord, Ph.D. addressed ...
... (PHILADELPHIA) Researchers from Thomas Jefferson University have identified ... in the growth and migration of prostate cancer cells, ... in the American Journal of Pathology . , ... of the protein when compared to normal prostate cells, ...
... Feb. 26 On Monday, March 2, the ... to become "The Healthiest Company in Green Bay." The firm ... them at that goal.The 30-person agency is collaborating with Health ... ( www.hatwork.com ). The title of "Healthiest Company in Green ...
... Physicians Offers Secure Message Capability to Facilitate ... Human Science, Inc. (HSI), a Rockville ... launch of an innovative software service that ... care in a secure environment. PatientCarenet.Org ...
... monitoring, and biostatistics for several early-stage clinical trials and registries ... ... Clinipace , a growing clinical research solutions company, today announced that ... aggregate, more than $2.8 million., , ,With a focus on emerging ...
... Feb. 26 Orthopaedic surgeon Michael L. Parks, MD, ... American Academy of Orthopaedic Surgeons (AAOS) ( ... Vegas. He will serve the Academy as Member-at-Large ... specializes in the reconstruction of arthritic conditions affecting the ...
Cached Medicine News:Health News:ACRO Presents at Japan CRO Association Commemorative Symposium 2Health News:Proepithelin encourages cell growth and migration in prostate cancer 2Health News:Arketype to Become Green Bay's Healthiest Company in One Year -- Wanna Bet? 2Health News:Arketype to Become Green Bay's Healthiest Company in One Year -- Wanna Bet? 3Health News:Human Science, Inc. Launches PatientCarenet.Org 2Health News:Human Science, Inc. Launches PatientCarenet.Org 3Health News:Clinipace Recently Awarded $2.8 Million to Manage Three New Clinical Projects 2Health News:Michael L. Parks, MD, Elected to the American Academy of Orthopaedic Surgeons Board of Directors 2
... Pulse Oximeters are high performance, easy-to-use ... proven signal processing to track even ... with Oxismart Advanced Signal Processing and ... identify electronic and optical noise, as ...
The Model 5340 is intended for continuous pulse oximetry and has visual and audible alarms to aid with patient monitoring....
The Model 340DT is a new desk top pulse oximeter that was designed for continuous pulse oximetry and has visual and audible alarms to aid with patient monitoring....
... The Model 130 has expanded memory capabilities ... has memory to retain oxygen saturation and pulse ... modes to best suit your needs:, ,1. ... minutes of information for a single patient, making ...
Medicine Products: